<![CDATA[Giants of Cancer Care Announces the 14th Annual Class of Inductees ]]>

Advertisement Press Release|Articles|May 8, 2026 Giants of Cancer Care Announces the 14th Annual Class of Inductees Author(s)OncLive Listen0:00 / 0:00 Key Takeaways OncLive’s Giants of Cancer Care recognizes oncology innovators whose discoveries and clinical leadership have redefined standards of care and accelerated progress toward durable, potentially curative outcomes. More than 115 eminent oncologists and prior honorees comprise the selection committee, underscoring peer-driven recognition across research excellence, education, mentorship, and patient-centered impact. The 2026 awards ceremony will be held May 28 at the Adler Planetarium in Chicago, providing a high-visibility forum to spotlight cross-disciplinary oncology leadership. Inductees include Javier Cortés, Scott Kopetz, Daniel George, Robert Haddad, William Wierda, Wyndham Wilson, Irene Ghobrial, Lajos Pusztai, Sue Yom, Kathleen Foley, Raphael Pollock, and Heather Wakelee.SHOW MORE Advertisement OncLive®, the nation’s leading multimedia resource for oncology professionals and Pfizer (platinum supporter), Daiichi-Sankyo (platinum supporter) and Regeneron (silver supporter), proudly announces the inductees of the 14th Annual Giants of Cancer Care recognition program.For more than a decade, Giants of Cancer Care has celebrated the visionaries whose groundbreaking discoveries, fearless innovation, and relentless dedication have transformed the landscape of oncology. These are the pioneers who have challenged convention, redefined standards of care, and pushed the field closer to a future once thought impossible for a future where curing cancer is no longer aspirational, but achievable.Selected by a prestigious committee of more than 115 leading oncologists and previous Giants honorees, this year’s inductees represent the very best of oncology research, clinical advancement, mentorship, and patient-centered care. Their work has not only extended lives but fundamentally changed the trajectory of cancer treatment for generations to come.The 2026 Giants of Cancer Care awards ceremony will take place Thursday, May 28, at 7 p.m. CDT at the Adler Planetarium in Chicago, IL, an iconic venue befitting a group of individuals whose contributions have helped illuminate the future of medicine. For more information on registration, click here.“These extraordinary leaders are not simply advancing oncology they are redefining what is possible,” said Mike Hennessy Jr., chairman and CEO of MJH Life Sciences®, parent company of OncLive. “The Giants of Cancer Care honorees represent decades of courage, discovery, collaboration, and unwavering commitment to patients. Their work has fundamentally altered the course of cancer care worldwide and continues to inspire hope for millions of families. It is because of pioneers like these that conversations about curing cancer feel increasingly within reach. We are profoundly honored to celebrate their legacy, leadership, and enduring impact on the future of oncology.”This year’s inductees by award category are:Breast Cancer: Javier Cortés, M.D., Ph.D. - International Breast Cancer Center/Vall d’Hebron Institute of OncologyCommunity Outreach/Education: Patrick I. Borgen, M.D. - Maimonides Medical CenterGastrointestinal Cancer: Scott Kopetz, M.D., Ph.D. - The University of Texas MD Anderson Cancer CenterGenitourinary Cancer: Daniel George, M.D. - Duke Cancer Institute and Duke University School of MedicineGynecologic Malignancies: Tate Thigpen, M.D. - (Retired) University of Mississippi School of MedicineHead & Neck Cancers: Robert Haddad, M.D. - Dana-Farber Cancer Institute/Harvard Medical SchoolLeukemia: William G. Wierda, M.D., Ph.D. - The University of Texas MD Anderson Cancer CenterLymphoma: Wyndham H. Wilson, M.D., Ph.D. - National Cancer InstituteMyeloma: Irene Ghobrial, M.D. - Harvard Medical School/Dana-Farber Cancer InstitutePrevention/Genetics: Lajos Pusztai, M.D., DPhil - Yale UniversityRadiation Oncology: Sue S. Yom, M.D., Ph.D., MAS - University of California, San Francisco, School of MedicineSupportive, Palliative, and/or Geriatric Care: Kathleen M. Foley, M.D. - Weill Medical College of Cornell UniversitySurgical Oncology: Raphael E. Pollock, M.D., Ph.D., FACS - The Ohio State University Wexner Medical CenterThoracic Malignancies: Heather Wakelee, M.D., FASCO - Stanford UniversityAbout OncLiveThe leading digital platform and multichannel resource for practicing oncologists, OncLive offers oncology professionals peer-to-peer insights, news and practical information they can use to offer the best patient care. OncLive is a brand of MJH Life Sciences, the largest privately held, independent, full-service health engagement network in North America dedicated to delivering trusted health care news across multiple channels.About Giants of Cancer CareGiants of Cancer Care celebrates the achievements of leading researchers and educators whose discoveries have helped propel the field of oncology and established the building blocks for future advances. Every year, a selection committee of more than 115 eminent oncologists, researchers and clinicians chooses honorees from several types of tumor and specialty categories. NewsletterStay up to date on the most recent and practice-changing oncology dataSubscribe Now! Advertisement Related ContentAdvertisementUT MD Anderson Shares Latest Research BreakthroughsByMD Anderson Cancer CenterMay 8th 2026OncLive Weekly News Quiz (5/8/2026): Test Your Knowledge on Key Breast, Lung, and Pancreatic Cancer UpdatesByOncLive StaffMay 8th 2026OncLive Polls Reveal Picks for Top Lung Cancer Abstracts at ASCO 2026ByCaroline SeymourMay 8th 2026Poll Results Highlight Breast Cancer Abstracts of Interest at ASCO 2026ByAshling Wahner May 8th 2026First-Line Danvatirsen Plus Pembrolizumab Fails to Improve Response Rates in Metastatic HNSCCByAshling Wahner May 8th 2026 Latest CMEVideoProactive Adverse Event Management for HER2+ BTC TreatmentsRahul Gosain, MD, MBA; Rohit Gosain, MD; Rachna T. Shroff, MD, MS, FASCOView moreMultimediaCommunity Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for MelanomaYana G. Najjar, MD; Douglas B. Johnson, MD, MSCI; Rahul A. Sheth, MD, FSIR View moreVirtual EventWisconsin Association of Hematology and Oncology1 Session is Available!View moreVideoCommunity Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Empire State Hematology & Oncology SocietySeth A. Wander, MD, PhD; Girish Kunapareddy, MDView moreVirtual EventArkansas Association of Cancer Professionals2 Sessions are Available!View moreVideoCommunity Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | South Carolina Oncology SocietySeth A. Wander, MD, PhD; Kit Lu, MDView moreVideo19th Annual New York GU Cancers Congress®Maha Hussain, MD, FACP, FASCO; Daniel P. Petrylak, MDView moreIn-Person + Virtual EventGo to PER in ChicagoMay 29-31, 2026View moreVideoCommunity Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Tennessee Oncology Practice SocietySeth A. Wander, MD, PhD; Kamel Abou Hussein, MDView moreVirtual EventKansas Society of Clinical Oncology1 Session is Available!View moreVideoA Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)Cindy Neunert, MD, MSCS; Hanny Al-Samkari, MD; Joseph Shatzel, MD, MCRView moreVideoEvolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular TestingEileen M. O’Reilly, MD; E. Gabriela Chiorean, MD, FASCO; Michael J. Pishvaian, MD, PhD; Brian Wolpin, MD, MPHView moreVideoCases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple MyelomaC. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MDView moreVideoTumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLCBalazs Halmos, MD, MS; Enriqueta Felip, MD, PhD; Julia Rotow, MDView moreVideoMedical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic ApproachesRami Komrokji, MD; Gabriela Hobbs, MD; John Mascarenhas, MD; Naveen Pemmaraju, MDView moreVideoPER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging StrategiesJonathan W. Goldman, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhDView moreVideoMedical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted TherapiesVinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA; Stephen J. Bagley, MD, MSCE; Angela Waanders, MD, MPH, MSView moreVideoMedical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple MyelomaC. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MDView moreVideoMedical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 DysregulationRebecca Heist, MD, MPH; Alex A. Adjei, MD, PhD, FACP; Sandip Patel, MD, FASCO; Jeremy Segal, MD, PhDView moreVideoCases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical InsightsGail J. Roboz, MD; Hagop Kantarjian, MD; Catherine Lai, MD, MPH; Amer Zeidan, MBBS, MHSView moreVideoMedical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast CancerWilliam J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhDView moreVideoGI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal CancerJohn H. Strickler, MD; Stacey A. Cohen, MD; Aparna Parikh, MD; Kanwal P.S. Raghav, MBBS, MDView moreVideoBreast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer TreatmentJoyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCOView moreMultimediaEstablishing the Rationale for ADC and ICI Combinations in TNBCVirginia Kaklamani, MD, DSc; Tiffany A. Traina, MD, FASCOView moreMultimediaBreaking Down the Rationale for Targeting TROP2 in TNBCFilipa Lynce, MD; Rita Nanda, MDView moreMultimediaDissecting Clinical Trial and Real-World Data for ADCs in TNBCFilipa Lynce, MD; Rita Nanda, MDView moreMultimediaEvaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBCAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MDView moreAudioBreaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLCRahul Gosain, MD, MBA; Rohit Gosain, MD; Hossein Borghaei, DO, MSView moreVideoOptimizing Treatment for Biliary Tract CancersGhassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhDView moreVideoCross-Disease Integration of Immunotherapy InnovationsGhassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhDView moreAudioPractical Considerations and Future Directions for New Treatment Strategies in SCLCRahul Gosain, MD, MBA; Rohit Gosain, MD; Misty D. Shields, MD, PhDView moreMultimediaExpert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBCAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DScView moreVideoBroadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular CarcinomaGhassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhDView moreMultimediaPER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – NursingAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCOView moreMultimediaExpert Roundtable and Panel Discussions: Current and Future Landscape of TNBCAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCOView moreVideoShow Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast CancerAna C. Garrido-Castro, MD; Pedram Razavi, MD, PhDView moreAudioNavigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New OptionsRahul Gosain, MD, MBA; Rohit Gosain, MD; Giannis Mountzios ΜD, PhDView moreVideoMedical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk AssessmentJason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MDView moreMultimediaReady for Radioligand Therapy? Patient Selection and Sequencing SimplifiedJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaWorking Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary CareJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaBURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate CancerJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaImaging Matters: Decoding PSMA PET for Better Decision-MakingJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaRadioligand Therapy 101: The Science Behind the StrategyJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCOView moreVideo Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease ContinuumTina Cascone, MD, PhD; Christina Baik, MD, MPH; David Planchard, MD, PhDView moreMultimediaCommunity Practice Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy–Strategies for the Multidisciplinary TeamYana G. Najjar, MD; Sapna Patel, MDView moreVideoA New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCsSandip Patel, MD, FASCO; Myung-Ju Ahn, MD; Giannis Mountzios, MD, MSc, PhD; Zofia Piotrowska, MD, MHSView moreVideoNavigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVOSriniVas R. Sadda, MD, FARVO; Mark R. Barakat, MD, FASRS; David A. Eichenbaum, MD, FASRSView moreVideoEnhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment StrategiesAna Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACPView moreVideo(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient OutcomesMichelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPOView more Advertisement Advertisement Trending on OncLive1Daraxonrasib Monotherapy Elicits Meaningful Responses in Previously Treated, RAS-Mutated Pancreatic Cancer2ASCO 2026 TNBC Deep Dive: Breast Cancer Experts Preview Practice-Informing Studies3FDA Completes Type A Meeting Following CRL for Tabelecleucel in EBV+ R/R Post-Transplant Lymphoproliferative Disease4Women With Bladder Cancer Face Diagnostic Delays as Symptoms Mimic UTIs, Experts Warn5Mentorship Is Key to Advance the Next Generation of Oncology Researchers